FWM
ALNY icon

Focused Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Focused Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$475 – 1044
2022
Q4 		$475 Buy
+2
New +$427 ﹤0.01% 953

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Focused Wealth Management's ALNY Position: Q1 2023 in Review

Focused Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 2 shares — an estimated $475 sold.

Focused Wealth Management first reported a position in ALNY in Q4 2022 and held it in 1 quarter. The position peaked at $475 in Q4 2022. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

  • Focused Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Focused Wealth Management sold 2 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $475.
  • Focused Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Focused Wealth Management's Alnylam Pharmaceuticals position peaked at $475 in Q4 2022.
  • 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on Focused Wealth Management's 13F filing for Q1 2023, filed 13 Apr 2023.